Dr. Eduardo Méndez has received a five-year, $2.2 million grant from the National Institutes of Health to develop the first targeted therapy that they hope will be effective for most patients with head and neck cancers.
‘Functional genomics’ method aims to marry three powerful techniques to speed personalized cancer treatments to patients
March 31, 2017
| By Rachel Tompa / Fred Hutch News Service
Dr. Christopher Kemp is confident that the answer to personalized cancer treatment is written in the molecules inside each patient’s tumor, we just need to figure out how to separate the wheat from the chaff.
Stigma, isolation and medical complexity may keep patients from getting all the care they need; recommendations aim to change that
April 8, 2016
| By Diane Mapes and Sabrina Richards / Fred Hutch News Service
Head-and-neck cancer survivors can have enormous aftereffects from the disease and its treatment. New survivorship guidelines just released by the American Cancer Society should help them get the support they need.
Drs. Colleen Delaney, Harlan Robins named 2016 Leaders in Health Care; Hutch study finds CMV viral load can act as surrogate endpoint for clinical trials; A new target for Tumor Paint: BLZ-100 lights up head and neck cancers; Dr. Stephen Tapscott appointed to NIAMS advisory council
Treatment could shrink tumors before surgery and reduce chemotherapy’s damaging side effects; clinical trial to launch later this year
Aug. 13, 2014
| By Dr. Rachel Tompa / Fred Hutch News Service
Using a technique that looks for genes that tumor cells need to survive, Fred Hutchinson Cancer Research Center scientists have identified a potential new drug for a class of difficult-to-treat head and neck cancers.